netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Ivacaftor found 11 matches

Open monograph to display formulary status BNF Category
  Ivacaftor Respiratory system - Mucolytics - 03.07
  Lumacaftor and Ivacaftor  (Orkambi®) Respiratory system - Mucolytics - 03.07
  Tezacaftor and Ivacaftor  (Symkevi®) Respiratory system - Mucolytics - 03.07
  Tezacaftor with Ivacaftor and elexacaftor  (Kaftrio®) Respiratory system - Mucolytics - 03.07
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section Commissioning statement: Ivacaftor, tezacaftor/ivacaftor, lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor for cystic fibrosis (03.07)
link in drug section Commissioning statement: Ivacaftor, tezacaftor/ivacaftor, lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor for cystic fibrosis (03.07)
link in drug section Commissioning statement: Ivacaftor, tezacaftor/ivacaftor, lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor for cystic fibrosis (03.07)
link in drug section Commissioning statement: Ivacaftor, tezacaftor/ivacaftor, lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor for cystic fibrosis (03.07)
link in drug section MHRA Drug Safety Update (Feb 2022): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on liver function testing (03.07)
link in drug section MHRA Drug Safety Update (Feb 2022): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on liver function testing (03.07)
link in drug section NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (03.07)


 

netFormulary